Finanzen von Belite Bio, Inc (BLTE)BLTEBelite Bio, Inc

Evaluating the bottom line, Belite Bio, Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -22.10%, provide a clear picture of how effectively BLTE converts its operational activities into shareholder value.

In the context of the broader market, BLTE competes directly with industry leaders such as KNSA and LQDA. With a market capitalization of $6.56B, it holds a significant position in the sector. When comparing efficiency, BLTE's gross margin of N/A stands against KNSA's 90.32% and LQDA's 93.27%. Such benchmarking helps identify whether Belite Bio, Inc is trading at a premium or discount relative to its financial performance.

Belite Bio reported a net loss of $28.4 million for Q2 2026, compared to $16.3 million a year ago, indicating widening losses despite a narrowing per-share loss from $0.70 to $0.50. The company ended Q2 2026 with $780 million in cash reserves, which provides a buffer for ongoing operations and R&D.